Experience with Investigations of Antibodiesafter Immunization with Vaccine FSME-Immun
Zkušenosti se sledováním protilátek po očkovánívakcínou FSME-Immun
V průběhu let 1997–1999 bylo získáno 607 sér od osob očkovaných vakcínou FSME-Immun protiklíšťové encefalitidě. Přítomnost protilátek byla hodnocena testy EIA TBEV-Ig TEST-Line, ClinicalDiagnostics, Immunozym FSME firmy Immuno a virusneutralizačním testem. Mezi výsledky testůnebyla nalezena dostatečná korelace, která by umožňovala validní hodnocení přítomnosti postvak-cinačních protilátek více metodami. Při použití testu Immunozym FSME bylo zjištěno, že v denaplikace 4. dávky vakcíny mělo 15 osob z 94 titr protilátek Ł 126 VIEU/ml, v den aplikace 5. dávkyto bylo 5 ze 13 očkovaných. Po aplikaci 3., 4. a 5. dávky získalo dostatečnou, tj. alespoň 3 rokytrvající, imunitu v závislosti na věku 64,1–97,9 % očkovaných. Vzhledem k tomu, že titry protilátekvyšší než 600 VIEU/ml mělo v jednotlivých věkových skupinách jen 20,0–61,7 % vyšetřených, nepo-važujeme u osob očkovaných rakouskou vakcínou za žádoucí prodlužovat časový interval mezijednotlivými revakcinacemi nad tři roky.
Klíčová slova:
klíšťová encefalitida – očkování – imunogenita.
Authors:
P. Pazdiora 1
; J. Januška 2; A. Kubátová 3
Authors‘ workplace:
Krajská hygienická stanice, Plzeň 2 Národní referenční laboratoř pro arboviry, Krajská hygienická stanice, Ostrava 3 Okresní hygienická stanice, Klatovy
1
Published in:
Epidemiol. Mikrobiol. Imunol. , 2000, č. 3, s. 110-114
Category:
Overview
During 1997–1999 607 sera were obtained from subjects immunized with vaccine FSME-Immun. Thepresence of antibodies was assessed using EIA TBEV-Ig TEST-Line tests, Clinical Diagnostics,Immunozym FSME of Immuno Co. and the virus neutralizing test. Between the results of testssufficient correlation was not found to allow valid evaluation of the presence of postvaccinationantibodies by several methods. When using the Immunozyme FSME test it was found that on theday of administration of the 4 th dose of vaccine 15 subjects of 94 had an antibody titre equal to or< 126 VIEU/ml, on the day of administration of the 5 th dose this was the case in 5 of 13 immunizedsubjects. After administration of the 3 rd , 4 th and 5 th dose adequate, i.e. at least three-year immunity,was acquired, depending on age, by 64.1–97.9% of the immunized subjects. As antibody titres higherthan 600 VIEU/ml in different age groups were recorded only in 20.0–61.7% of the subjects, theauthors do not consider it desirable in subjects immunized with the Austrian vaccine to prolong thetime interval between vaccinations beyond three years.
Key words:
tick-borne encephalitis – vaccination – immunogenicity.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2000 Issue 3
- Invasive Pulmonary Aspergillosis – A Common Accompanying Infection in Patients with Severe or Critical Course of COVID-19
- Intestinal Infection of Multi-Resistant NDM-Producing K. pneumoniae in a Patient with NK/T Lymphoma – Case Study
- Overview of Current Treatment Options for MRSA-Induced Pneumonia
- Bacterial Community Pneumonia and Its Treatment in Children
- Current Insights into the Etiology of Community Pneumonia: Pneumococci Still Leading?
Most read in this issue
- Experience with Investigations of Antibodiesafter Immunization with Vaccine FSME-Immun
- Dermatological Manifestationsof Lyme Borreliosis in Patients of the First Dermatovenerological Clinic, MedicalFaculty Comenius University, Bratislava, Slovak Republic, in 1996–1998
- Prevention of Herpes by Poliovaccine
- DiagnosticMedium for Arcanobacterium haemolyticum and for Other Bacterial Species Reac-ting by Haemolytic Synergism with equi Factor of Rhodococcus equi